



A case report of an unusual kidney tumor: Mucinous tubular and spindle cell carcinoma

Prikaz bolesnika sa retkim tumorom bubrega – mucinozni tubularni vretenastoćelijski karcinom

Tanja Lakić^{*†}, Aleksandra Ilić^{*†}, Mirjana Zivojinov^{*†}, Jelena Ilić Sabo^{*†},
Dimitrije Jeremić^{*‡}, Dragan Grbić[‡]

^{*}University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia; Clinical Center of
Vojvodina, [†]Center for Pathology and Histology, [‡]Urology Clinic, Novi Sad, Serbia

Abstract

Introduction. Mucinous tubular and spindle cell carcinoma of the kidney (MTSCC) is a rare and recently described subtype of renal cell carcinoma (RCC). As its name indicates, the tumor is composed of three morphological structures: tubules consisted of cuboidal cells, spindle cells, and extracellular mucus. **Case report.** A 59-year-old female patient was admitted to the Emergency Center of the Clinical Center of Vojvodina due to injuries sustained in a traffic accident. After diagnostic procedures, computer tomography (CT) revealed a large asymptomatic cyst of the upper pole of the left kidney as an incidental finding. Four months later, after recovering from traumatic injuries, a control CT confirmed a well-circumscribed tumor, 90 mm in diameter, confined to a kidney, and a radical nephrectomy was performed. Histopathological evaluation showed that the necrotic tumor mass consisted of tubules made of cuboidal cells and cords made of spindle cells separated by pale mucinous material in some areas, while other tumor parts were of dense cellularity without mucin. No atypia was found. **Conclusion.** MTSCC is a variant of papillary RCC, thus, it is usually mistaken with papillary RCC with sarcomatoid differentiation. Because of the same immunoprofile as papillary RCC, histomorphology is imposed as the gold standard for making the diagnosis. MTSCC is a tumor with a generally favorable prognosis, and complete surgical excision appears to be adequate treatment, but single cases with metastatic disease have been reported. In this case, there were no signs of the disease one year after surgery.

Key words:

kidney neoplasms; carcinoma, renal cell;
adenocarcinoma mucinous; diagnosis; nephrectomy;
treatment outcome.

Apstrakt

Uvod. Mucinozni tubularni vretenastoćelijski karcinom bubrega (MTSCC) je redak i nedavno opisan podtip karcinoma bubrežnih ćelija (RCC). Kao što mu ime kaže, tumor se sastoji od tri morfološki različite strukture: tubuli sačinjeni od kubičnih ćelija, zatim vretenaste ćelije i ekstracelularna sluz. **Prikaz bolesnika.** U radu je prikazana 59-godišnja bolesnica koja je primljena u Urgentni centar Kliničkog centra Vojvodine zbog povreda nastalih u saobraćajnoj nesreći. Nakon dijagnostičkih procedura, kompjuterskom tomografijom (CT) otkrivena je asimptomatska velika cista gornjeg pola levog bubrega kao uzgredni nalaz. Četiri meseca kasnije, nakon oporavka od traumatskih povreda, kontrolnim CT pregledom potvrđen je dobro ograničen tumor, promera 90 mm, ograničen na bubrež, zbog čega je izvršena radikalna nefrektomija. Histopatološkom analizom ustanovljeno je da se radi o nekrotičnoj tumorskoj masi sastavljenoj od tubula sačinjenih od kubičnih ćelija i snopova vretenastih ćelija, razdvojenih bleđim mucinoznom materijalom u nekim područjima, dok su ostali delovi tumora bili bez produkcije mucina i prisustva atipije. **Zaključak.** MTSCC je varijanta papilarnog RCC, pa se obično pogrešno dijagnostikuje kao papilarni RCC sa sarkomatoidnom diferencijacijom. Zbog istog imunoprofila sa papilarnim RCC, histomorfologija predstavlja zlatni standard za postavljanje dijagnoze. MTSCC je tumor sa, generalno povoljnom prognozom i kompletna hirurška ekscizija je adekvatan tretman lečenja, iako su opisani pojedinačni slučajevi metastatske bolesti. Kod ove bolesnice nije bilo znakova bolesti godinu dana nakon operacije.

Cljučne reči:

bubreg, neoplazme; karcinom bubrežnih ćelija;
adenokarcinom, mucinozni; dijagnoza; nefrektomija;
lečenje, ishod.

Introduction

Mucinous tubular and spindle cell carcinoma of the kidney (MTSCC) is a rare and recently described subtype of renal cell carcinoma (RCC), which has been recognized as a specific entity in the 2004 World Health Organization (WHO) classification of renal cell carcinoma¹. To this date, there are approximately 100 cases described in the literature². The tumor mostly affects adults with a mean age of 53 years (range 18–82) with marked female predominance (4:1) as in our case¹, in contrast to RCC. MTSCC is a cytologically low-grade neoplasm, but both high-grade MTSCC and MTSCC with sarcomatoid differentiation are described^{3,4}.

Clinical symptoms such as flank pain, abdominal mass, and hematuria are rare but possible⁵; most MTSCC tumors are solitary and were incidentally discovered by ultrasound or computer tomography examinations.

As its name indicates, the tumor is composed of three morphologically different structures: tubules consisted of cuboidal cells, spindle cells, and extracellular mucus and it mostly resembles type 1 papillary RCC but without true papilla formation⁶. In both cuboidal and spindle cells, nuclear atypia and mitoses are rare. The proportion of those morphological parts is different in different cases, and hemorrhage and/or necrosis, minor areas with clear cell and oncocytic change, are possible to find as well^{7,8}. Focal papillations may be found and are usually mistaken with papillary RCC with sarcomatoid differentiation.

Although the literature shows contradictory reports regarding its histogenesis^{9,10}, the morphological, immunohistochemical, and genetic features suggest differentiation from collecting duct epithelium. Moreover, immunohistochemical analyses show expression of epithelial membrane antigen (EMA), alpha-methylacyl-coenzyme A racemase (AMACR), cytokeratin 7 (CK7), PAX-8, and vimentin in 80–100% of the cases, which confirms a possible origin from

distal convoluted epithelial cells¹¹. AMACR expression can also be seen in proximal tubule cells. Therefore, there is a belief that it could be a variant of papillary RCC¹⁰. CD-10 and RCC are often negative.

MTSCC is a renal tumor with an excellent prognosis, but it is not exclusive because there are single cases with the metastatic disease described.

Case report

In December 2017, a 59-year-old female patient was admitted to the Emergency Center of the Clinical Center of Vojvodina due to injuries sustained in a traffic accident. After diagnostic procedures, a serial fracture of ribs was registered, some subcutaneous hematomas, and no signs of internal bleeding. Moreover, computer tomography (CT) revealed a large cyst on the left kidney as an incidental finding without symptoms (Figure 1A). After recovering from traumatic injuries, the patient came to the Urology Clinic of the Clinical Center of Vojvodina because of hematuria. In April 2018, a control CT was made, and it confirmed the existence of a round, clearly demarcated, inhomogeneous mass, 85 millimeters in size, which changed the kidney contour and made pressure on calyces of the medium part and the upper pole of the kidney (Figure 1B). The lumen of the cyst was filled with debris-like material, and surgical treatment was indicated. A left radical nephrectomy was performed in June 2018, and the specimen was sent to the Pathology Department. Grossly, it was a well-circumscribed tumor, 90 mm in diameter, confined to the kidney with the necrotic content inside. A detailed histopathological examination verified the tumor mass characterized by a mixture of compressed anastomosing and tightly packed and parallelly arranged tubular structures consisted of cuboidal cells with round, pale nuclei (Figure 2A). Atypia was minimal. Tubular structures were separated by thin bundles of spindle cells and variable amounts of extra-




Fig. 1 – A) The first computer tomography (CT) scan showed a big cyst of the left kidney; B) Control CT with the same kidney cyst.

cellular blue-gray Alcian-blue-periodic-acid-Schiff positive mucinous matrix (Figure 2B). Extensive areas of necrosis were present without lymphovascular invasion. Special immunohistochemical stainings showed positivity for CK7 (Figure 2C), AMACR (Figure 2D), Vimentin (Figure 2E), as well as EMA and E-cadherin. RCC and CD-10 were negative. Based on the histological and immunohistochemical description of the tumor, the diagnosis of mucinous tubular and spindle cell renal cell carcinoma was made.

MTSCC, thus histomorphology appears to be the gold standard for making the diagnosis. It is a tumor with a generally favorable prognosis, and complete surgical excision appears to be adequate treatment, but cases with metastatic disease have been reported¹². Generally, it is estimated that 20–40% of patients with RCC develop metastases after surgery¹³. An unfavorable course of the disease like recurrence, regional lymph nodes, and distant sites metastases, or even death, are associated with atypical histological fea-




Fig. 2 – A) Spindle cell tumor component [hematoxylin and eosin (HE), 10×]; B) Tubular structures of cuboidal cells (HE, 10×); C) Extracellular mucinous matrix (HE, 10×); D) Antibody cytokeratin 7 (CK7) (IHC, 20×); E) Antibody alpha-methylacyl-coenzyme (AMACR) (IHC, 20×); F) Antibody Vimentin (IHC, 10×). IHC – immunohistochemistry.

Discussion

Mucinous tubular and spindle cell renal cell carcinoma is a rare renal tumor. The histogenesis of this tumor is controversial. It has been shown differentiation toward the distal nephron, which led to different tumors, including low-grade tubular mucinous renal neoplasms and low-grade myxoid tumor. Recently, the literature showed immunohistochemical overlap with papillary RCC pointing to proximal tubular differentiation. In fact, MTSCC is a variant of papillary RCC. Although a close relationship to papillary RCC has been suggested, clinically, morphologically, and genetically, it is a distinct renal neoplastic entity. Histopathological examination is imperative for making the correct diagnosis. Immunohistochemistry is not a very useful method for discriminating between papillary RCC and

tures such as high nuclear grade and sarcomatoid transformation^{14, 15}. Although an innocent outcome is likely, a close follow-up is recommended. In our patient, there were no signs of the disease one year after surgery.

Conclusion

MTSCC is a variant of papillary RCC, hence it is usually mistaken with papillary RCC with sarcomatoid differentiation. Because of the same immunoprofile as papillary RCC, histomorphology is imposed as the gold standard for making the diagnosis. MTSCC is a tumor with a generally favorable prognosis, and complete surgical excision appears to be adequate treatment, but cases with metastatic disease have been reported. In this patient, there were no signs of the disease one year after surgery.

REFERENCES

1. Eble JN, Sauter G, Epstein JI, Sesterhenn LA. World Health Organization Classification of Tumours Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press; 2004.
2. Chander B, Bharti R, Preet K, Deb P. Mucinous tubular and spindle cell carcinoma of kidney: A case report of an unusual tumor. J Can Res Ther 2015; 11(3): 659.
3. Dhillon J, Amin MB, Selbs E, Turi GK, Paner GP, Renter VE. Mucinous tubular and spindle cell carcinoma of the kidney with sarcomatoid change. Am J Surg Pathol 2009; 33(1): 44–9.
4. Kuroda N, Hes O, Michal M, Nemcova J, Gal V, Yamaguchi T, et al. Mucinous tubular and spindle cell carcinoma with Fuhrman nuclear grade 3: a histological, immunohistochemical, ultrastructural and FISH study. Histol Histopathol 2008; 23(12): 1517–235.
5. Zhao M, He X, Teng X. Mucinous tubular and spindle cell renal cell carcinoma: a review of clinicopathologic aspects. Diagn Pathol 2015; 1: 168.
6. Lima MS, Barros-Silva GE, Pereira RA, Ravinal RC, Tucci S Jr, Costa RS, et al. The imaging and pathological features of a mu-

- cinous tubular and spindle cell carcinoma of the kidney: A case report. *World J Surg Oncol* 2013; 11: 34.
7. *Fine SW, Argani P, DeMarzo AM, Delahunt B, Sebo TJ, Reuter VE, et al.* Expanding the histologic spectrum of mucinous tubular and spindle cell carcinoma of the kidney. *Am J Surg Pathol* 2006; 30(12): 1554–60.
 8. *Kuroda N, Tamura M, Hes O, Michal M, Kawada C, Shuin T, et al.* Renal cell carcinoma with extensive clear cell change sharing characteristics of mucinous tubular and spindle cell carcinoma and papillary renal cell carcinoma. *Pathol Int* 2009; 59(9): 687–8.
 9. *Shen SS, Ro JY, Tamboli P, Truong LD, Zhai Q, Jung SJ, et al.* Mucinous tubular and spindle cell carcinoma of kidney is probably a variant of papillary renal cell carcinoma with spindle cell features. *Ann Diagn Pathol* 2007; 11(1): 13–21.
 10. *Paner GP, Srigley JR, Radbakerishnan A, Cohen C, Skinnider BF, Tickoo SK, et al.* Immunohistochemical analysis of mucinous tubular and spindle cell carcinoma and papillary renal cell carcinoma of the kidney-significant immunophenotypic overlap warrants diagnostic caution. *Am J Surg Pathol* 2006; 30(1): 13–9.
 11. *Ferlicot S, Allory Y, Comp  rat E, Mege-Lechevalier F, Dimet S, Sibony M, et al.* Mucinous tubular and spindle cell carcinoma: A report of 15 cases and a review of the literature. *Virchows Arch* 2005; 447(6): 978–83.
 12. *Kenney PA, Vikram R, Prasad SR, Tamboli P, Matin SF, Wood CG, et al.* Mucinous tubular and spindle cell carcinoma (MTSCC) of the kidney: a detailed study of radiological, pathological and clinical outcomes. *BJU Int* 2015; 116(1): 85–92.
 13. *Levakov I, Vojinovic S, Marusic G, Popov M, Levakov O, Popov M, et al.* Safety profile of temsirolimus in patients with metastatic renal cell carcinoma. *J BUON* 2016; 21(6): 1442–8.
 14. *Ursani NA, Robertson AR, Schieman SM, Bainbridge T, Srigley JR.* Mucinous tubular and spindle cell carcinoma of kidney without sarcomatoid change showing metastases to liver and retroperitoneal lymph node. *Hum Pathol* 2011; 42(3): 444–8.
 15. *Thway K, du Preez J, Larkin JM, Fisher C, Livni N.* Metastatic renal mucinous tubular and spindle cell carcinoma. Atypical behavior of a rare, morphologically bland tumor. *Ann Diagn Pathol* 2012; 16(5): 407–10.

Received on May 23, 2019.
Accepted September 30, 2019.
Online First October, 2019.